TECH vs. TEVA: Bio-Techne vs. Teva Pharmaceutical Stock Comparison

Company Profile

Bio-Techne (TECH) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but TECH is classified in Life Sciences Tools & Services while TEVA is classified in Pharmaceuticals.

Bio-Techne (TECH) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bio-Techne (TECH) at 8.33% and Teva Pharmaceutical (TEVA) at 6.65% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Bio-Techne (TECH) at 14.00% retains a top-quartile share of revenue as profit, ahead of Teva Pharmaceutical (TEVA) at 2.94%, which keeps about the industry-typical share.

Teva Pharmaceutical (TEVA) at 27.40% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bio-Techne (TECH) at -0.38% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Bio-Techne (TECH) reports EPS growth of 152.17%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Bio-Techne (TECH) at 2.28 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Bio-Techne (TECH) at 0.13 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.

Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Bio-Techne (TECH) at 62.74 sits in the richer P/E ratio quartile, and Teva Pharmaceutical (TEVA) at 99.09 is richer still, above its industry range.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Bio-Techne (TECH) at 9.31 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Bio-Techne (TECH) at 5.28 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics